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Abstract 133neutropenia and diarrhea, which has been demonstrated to be related to the enzymatic activity of UGT1A1 (uridine
diphosphate glucuronosyl transferase).
Cases Description: We herein report three metastatic CRC (mCRC) patients with severe liver dysfunction and prolonged
hyperbilirubinemia that were successfully treated with a combination of bevacizumab and FOLFIRI regimen under the
identification of the favorable UGT1A1 genotype (6/6 or 6/7).
Conclusion: We used UGT1A1 genotype as a predictor of toxicity in these mCRC patients with severe liver dysfunction and
jaundice to ascertain whether genotype-adjusted dosages of the irinotecan could assist physicians in establishing a safe and
effective therapy.
